Clinical Trials Browser

Phase 2 × INDUSTRY × trastuzumab duocarmazine × Clear all

NCT04205630 2024-05-30

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Phase 2 Completed

64 enrolled 13 charts

Endometrial Neoplasms